COVID-19 Resources

HAP is actively monitoring developments and continues to engage with Pennsylvania Department of Health and the Centers for Disease Control and Prevention to provide members with the most current information and resources.

About COVID-19

The Pennsylvania Department of Health provides information about the coronavirus disease 2019 (COVID-19) and state health officials’ efforts to monitor the spread of the virus.

Also on the Department of Health's COVID-19 page:

  • County and zip code maps of cases
  • County data in table form
  • The latest stay-at-home orders by county
  • Testing and contact tracing plans for the commonwealth

This information is updated regularly.

In addition, the Centers for Disease Control and Prevention provides extensive information about COVID-19 at its website, including:

COVID-19's Impact on Hospitals

The COVID-19 pandemic is threatening the sustainability of Pennsylvania hospitals and the communities they serve. View HAP's new infographic in our Resource Center.

HAP Infographic about Hospital Losses from the COVID-19 Pandemic

Online Resources

Reporting

Multisystem Inflammatory Syndrome Associated with COVID-19 Case Report Form, May 28, 2021

COVID-19 Treatments

Casirivimab and Imdevimab—Administration together for mild to moderate coronavirus disease in adults and pediatric patients 12 years of age and older and weighing at least 40 kg with positive viral testing results, and who are at high risk for progressing to severe COVID-19.

Baricitinib (Olumiant) in combination with remdesivir (Veklury)—Emergency use for suspected or laboratory-confirmed COVID-19 in hospitalized adults and pediatric patients 2 years of age or older requiring oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)

Bamlanivimab—Treatment of mild to moderate COVID-19 in adult and pediatric patients with positive SARS-CoV-2 viral testing results and age 12 years and older and weighing at least 40 kilograms

COVID-19 convalescent plasma—Treatment of hospitalized patients with COVID-19

Regiocit replacement solution—Replacement solution only in adult patients treated with continuous renal replacement therapy (CRRT)

Fresenius Kabi Propoven 2%—Maintaining sedation via continuous infusion in patients older than 16 years with suspected or confirmed COVID-10 who require mechanical ventilation in an ICU

Remdesivir for certain hospitalized COVID-19 Patients—Emergency use for treatment of suspected or laboratory confirmed COVID-19 in hospitalized pediatric patients weighing 3.5 kg to less than 40 kg or hospitalized pediatric patients less than 12 years of age weighing at least 3.5 kg

Vaccine Information

Illustrative provider COVID-19 Vx ordering timeline, Pennsylvania Department of Health, (Members only)

Pennsylvania Department of Health Vaccine Toolkit, Updated April 12, 2021

COVID-19 Vaccines, U.S. Food and Drug Administration, May, 2021

Vaccinating Pregnant and Lactating Patients Against COVID-19, American College of Obstetricians and Gynecologists, April 28,  2021

Janssen

Fact Sheet for Health Care Providers, Revised April 23, 2021 

Fact Sheet for Recipients and Caregivers, Revised April 23, 2021 

FDA Emergency Use Authorization, February 27, 2021 

Moderna

Moderna COVID-19 Vaccine Frequently Asked Questions, Updated April 13, 2021 

Fact Sheet for Health Care Providers, Revised March 31, 2021

Fact Sheet for Recipients and Caregivers, Revised March 26, 2021

FDA Emergency Use Authorization Letter, December 18, 2020

Pfizer-Biontech COVID-19 Vaccine

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine—United States, December 2020

Fact Sheet for Health Care Providers, Revised May 10, 2021

Fact Sheet for Recipients and Caregivers, Revised May 10, 2021

FDA Emergency Use Authorization Letter, Amended, February 25, 2021

Supplies & PPE

HAP Resources

Federal Resources


Regulatory Policy

The Centers for Medicare & Medicaid Services:

HAP COVID-19 News

October 14, 2021

FDA Panel OKs Moderna Booster for High-Risk Groups

The U.S. Food and Drug Administration’s (FDA) advisory panel recommended approving a half-dose booster of Moderna’s COVID-19 vaccine for older Americans, health care workers, and other high-risk groups.

+